Celecoxib sales will expand through 2036, with crystalline at 64.0% within the form segment, 99.5% or higher leading the purity grade segment and finished-dosage manufacturers at 61.0% in 2026. The market is estimated at USD 13.21 million in 2026 and is forecast to record a 3.2% CAGR between 2026 and 2036.